Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


Immunotherapy Shows Promise for TNBC Patients


 

FDA Approves Tecentriq® as First Immunotherapy Regimen for Breast Cancer

A breakthrough therapy is offering unprecedented hope to women with metastatic triple negative breast cancer (TNBC).

Last month, the FDA granted Genentech, a member of the Roche Group, accelerated approval to Tecentriq® (atezolizumab) plus chemotherapy for the treatment of adults with unresectable locally advanced or metastatic TNBC in people whose tumors express the protein PD-L1. The Tecentriq combination is the first cancer immunotherapy regimen to be approved in breast cancer, which represents a giant step forward in the treatment of a historically difficult-to-treat form of the disease.


Breast Cancer 101

Breast cancer is the most common cancer among women worldwide. According to the American Cancer Society, approximately 271,000 people in the United States will be diagnosed with breast cancer, and more than 42,000 will die from the disease in 2019.


Erika Hamilton, MD

Erika Hamilton, MD, director of the Breast Cancer and Gynecologic Cancer Research Program at Sarah Cannon Research Institute and an IMpassion130 (Tecentriq) study investigator, said triple negative breast cancer, which accounts for 15 to 20 percent of breast cancers, is the most medically challenging to treat, partially because it tends to be more aggressive than more common types of the cancer.

Breast cancer can be diagnosed based on the presence or absence of three receptors - estrogen, progesterone and HER2. These receptors are the drivers for the development and growth of breast cancer. Triple negative breast cancer is diagnosed when a pathology report shows a negative result for all three of the common receptors.


Treatment Options

While targeted therapies exist to decrease reoccurrence of hormonally-driven and HER2 breast cancers, patients with TNBC have historically received only chemotherapy. "The tricky thing about triple negative breast cancer is that we haven't had any targeted medications to treat it like we do for other types of breast cancer," Hamilton said.

"Triple negative is the worst prognosis, and women with metastatic TNBC typically have a survival rate of 18 months," she continued. "Biologically, it just tends to be more aggressive, and it's a more heterogeneous breast cancer group since all triple negatives aren't the same. They're a basket of cancers that don't express receptors, so it's been challenging to find a therapy that's effective for a large enough population."


Immunotherapy in Breast Cancer

Now, Hamilton and other oncologists are turning to atezolizumab - an immunotherapy already approved for treatment of certain lung and bladder cancers. Immunotherapy is a type of biological therapy that uses targeted drugs to convince the body's immune system to recognize that there is something foreign in the body (cancer) and to attack the cells threatening it.

Technically speaking, Tecentriq is a monoclonal antibody designed to bind with the protein PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells, which are essential for immunity.

During the Phase III IMpassion130 trial, which involved 902 participants, the IV therapy was administered in combination with the common chemotherapy drug nab-paclitaxel with notable results. Progression-free survival increased from 5 to 7.5 months, but what impressed Hamilton was that it translated into overall survival to a more significant degree.

The 41 percent of TNBC patients with the PD‑L1 protein, which helps cells hide from immune attack, extended life expectancy from 15.5 to 25 months. In fact, one TNBC trial participant under Hamilton's care is still working full-time three years after starting atezolizumab and no longer receives chemotherapy.

She said side effects of atezolizumab also make the therapy more appealing over chemo. "Day-to-day, it's tolerated really well, with no nausea or hair loss," Hamilton said, noting that some patients do experience fatigue or symptoms of immune activation, such as low-grade fever or body aches. "Compared to receiving chemo on a day-to-day basis, patients feel very good on it, and it's something you can stay on longer than chemo," she said.

A Genentech spokesperson said the company currently has several other large, ongoing studies of Tecentriq in TNBC, including early and advanced stages of the disease. In addition to Tecentriq, they're also studying the AKT-inhibitor ipatasertib in TNBC.

WEB:

Sarah Cannon

Genentech

NCI Release on FDA Approval

 
Share:

Related Articles:


Recent Articles

AMA Announces First Chief Health Equity Officer

The American Medical Association (AMA) today announced the hiring of Aletha Maybank, M.D., M.P.H., as its first ever chief health equity officer.

Read More

AMA Calls Pain Task Force Recommendations A Road Map for Future Policy

May 9, 2019 ... The AMA strongly backs the comprehensive, common-sense proposals the Interagency Pain Task Force discussed today, sending a clear signal to the physician community that policy makers understand the treatment required for patients in pain.

Read More

Technology Better Than Tape Measure for Identifying Lymphedema Risk

Bioimpedance spectroscopy (BIS) is better than a tape measure for assessing a woman's risk for developing lymphedema, painful swelling in the arm after breast cancer surgery, according to interim results of a study led by Sheila Ridner, PhD, RN, Martha Ingram Professor and director of the PhD in Nursing Science Program at Vanderbilt University School of Nursing.

Read More

Immunotherapy Shows Promise for TNBC Patients

New immunotherapy regimen approved for the treatment of historically untreatable triple negative breast cancer.

Read More

Reimagining Residency

The AMA has spent the last several years accelerating change in medical education. Now the time has come to reimagine residency as the national organization works to transform physician training & practice.

Read More

Accessing the Spectrum of Quality Care

With the ACOG meeting ... and her year of presidency ... just wrapped, Dr. Lisa M. Hollier, MD, MPH, FACOG shares reflections on the past year and the state of women's health.

Read More

ACS ResearcHERS Program Bringing Awareness to Women in Science

Women now comprise 50 percent of ACS funded research.

Read More

Physician Spotlight: Serving the City

Longtime TennCare leader & public health expert has now been tapped to lead health efforts for Davidson County residents.

Read More

Diverse by Design

THA's Agenda 21 Opens Doors, Launches Careers

Read More

Belmont, Lipscomb Partner on Honduran Pharmacy

The Belmont University and Lipscomb University Colleges of Pharmacy have recently announced a collaborative partnership with Jovenes en Camino to build and support a locally-run pharmacy in El Zamorano, Honduras.

Read More

Email Print
 
 

 

 


Tags:
atezolizumab, Erika Hamilton, Immunotherapy, IMpassion130, Sarah Cannon Research Institute, Tecentriq®, TNBC, Triple Negative Breast Cancer
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: